Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-HTP challenge before and after ECT in major depressive episode
NL-OMON33643Withdrawn
- Sponsor
- Centre for Human Drug Research
- Start
- Mar 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of 5-hydroxytryptophan, carbidopa and granisetron in major depressive disorder (MDD) and bipolar disorder (BD) (2 arms), sponsored by Centre for Human Drug Research. Primary endpoints: Plasma ACTH, Serum total cortisol and 5 more. Planned start Mar 2009; status: withdrawn.
02
Drugs
5-hydroxytryptophancarbidopagranisetron
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NL-OMON33643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33643.